- Jun 22
- 10 min read
Updated: Jul 30
Key Takeaways18-year-old with Stage IV Burkitt lymphoma: Wei Junhao had high-risk lymphoma involving the chest, abdomen, spinal lymph nodes, brain membranes, and later the brain itself. More than 8 months of unsuccessful treatment: He received multiple chemotherapy rounds, targeted drugs, radiation, and brain-penetrating medicines, but his lymphoma continued to progress. TP53 mutation signaled treatment resistance: Genetic testing found a TP53 mutation, which helped explain why standard therapies were not controlling the cancer. Brain relapse created an immediate life-threatening risk: Imaging showed a brain mass measuring more than 7 cm, pressing against the brain ventricles and creating a risk of brain herniation. Dual-target CAR-T used CD19 and CD20: The compassionate-use treatment was designed to attack two lymphoma markers at once, helping reduce the risk of cancer escape through loss of a single target. Treatment involved severe neurological toxicity: Within days of infusion, Wei developed seizures and loss of consciousness, requiring continuous monitoring and intensive medical management. The lymphoma cleared after CAR-T therapy: Follow-up imaging showed that the brain mass had disappeared after treatment. ChinaCureLink, affiliated with Medebound HEALTH, supports international care coordination: With 10+ years of experience and 3,000+ patients served worldwide, the team helps families organize medical records, specialist reviews, hospital access, translation, and treatment planning in China. |
Introduction
The pain started in his teeth.
Wei Junhao (alias) was eighteen years old, and he assumed — as eighteen-year-olds do — that it was nothing serious. A toothache. Something a dentist could fix. But the clinic near his home in central China couldn't find the source. There was nothing wrong with his teeth. They sent him on.
In Beijing, the tests were more thorough. And the answer that came back had nothing to do with his mouth at all.
Burkitt lymphoma, Stage IV, high-risk. The cancer had already spread to his chest, the lining around his heart, his abdomen, the lymph nodes along his spine, the membranes of his brain. He was told the disease was growing fast — faster than most. He was eighteen years old, and every room in the house was already on fire.
Patient Background
Before the diagnosis, Wei Junhao was the kind of young man who moved through life quickly — curious, impatient in the way of teenagers who feel the future pulling at them. He lived with his parents, was finishing his secondary education, and had the vague, enthusiastic ambitions of someone who hasn't yet had to choose.
His parents were ordinary people with ordinary routines. They would later describe the months before his diagnosis as peaceful in retrospect — the kind of peace you only notice once it is gone.
After the diagnosis, that world contracted. Everything became appointments, transfers, second opinions. His parents moved their lives around his treatment schedule. They brought him to Beijing. They waited. They hoped.
Initial Diagnosis
Burkitt lymphoma is one of the fastest-growing cancers known to medicine. In its high-risk form — which Wei's was — it can double in size within days. The standard treatment is aggressive, multi-drug chemotherapy. For many patients, it works. For Wei, it didn't.
Round after round of chemotherapy was given. Then targeted drugs. Then radiation focused on specific areas. Then drugs specifically chosen because they can cross the blood-brain barrier — the protective membrane surrounding the brain — because the cancer had now invaded the brain itself. Nothing held.
A genetic test added another layer of bad news: his tumor carried a mutation in a gene called TP53 — a change that disrupts one of the cell's core defense systems and makes cancer resistant to most standard treatments. This explained why nothing was working. It also narrowed the path forward to almost nothing.
Eight months after his initial diagnosis, more than a month after his brain relapsed, Wei Junhao had failed every available treatment. The cancer was now growing inside his brain tissue itself. His family was told, in the careful language of medicine, that options were running out.
"The scans showed a mass inside the brain more than seven centimetres across, pressing against the ventricles. A brain herniation — in which swelling forces brain tissue out of its normal space — could happen without warning. That kind of event is often fatal."
The Turn: Choosing Treatment in China
In February 2019, Wei Junhao's family brought him to a specialist blood disease JCI-accredited hospital in Hebei province, near Beijing. He was eighteen years old, deeply ill, and carrying a diagnosis that most oncologists would have described as terminal.
They came because they had heard of Dr. Chen Yuzhang (alias) — a specialist in cellular therapies and complex blood cancers who had been working with a relatively new type of treatment that reprogrammed the immune system itself to fight cancer. They had not run out of hope. But they were close.
Dr. Chen reviewed the case. He agreed that standard treatments had nothing left to offer. But he didn't stop there.
The Treatment Journey
A Meeting That Changed Everything
Dr. Chen convened the entire department. Physicians, nurses, specialists — everyone who might have a perspective sat down together to think through the case. The question on the table was whether to attempt something that had almost no precedent: CAR-T cell therapy directed at a brain tumor of this size, in this location, in a patient who didn't even meet the standard eligibility criteria for clinical trials.
CAR-T therapy — chimeric antigen receptor T-cell therapy — works by taking immune cells from the patient's own blood, reprogramming them in a laboratory to recognise and attack cancer, and then returning them to the body. It had shown remarkable results in some blood cancers. But in central nervous system tumors, especially tumors as large as Wei's, the experience was extremely limited. The risk of severe neurological reactions was real. The risk of death from the treatment itself was real.
The team discussed it at length. Wei's parents were brought into the conversation. They understood the risks. They gave their consent.
The specific approach chosen was a dual-target CAR-T therapy — cells engineered to attack two proteins simultaneously on the surface of the cancer cells: CD19 and CD20. By attacking both at once, the treatment reduces the chance that the cancer can escape by mutating away from one target.
Because this treatment fell outside standard protocols, it was given as what is called compassionate use — treatment offered in exceptional circumstances when no other option remains.
Crisis and Turning Point
The infusion was given. Then, within days, Wei developed severe neurological toxicity — seizures, loss of consciousness. The reprogrammed immune cells were doing what they were designed to do, but the inflammatory response inside his brain was overwhelming. He was critically ill.
The team worked continuously. Medications were adjusted. His condition was monitored around the clock. There were hours when no one was sure he would survive the treatment itself. Slowly, the seizures subsided. His consciousness returned. The weeks that followed were cautious, watchful.
The Scans
When the imaging results came back, they showed something no one had been able to predict with certainty: the cancer was gone. The mass that had compressed his brain ventricles and threatened his life had cleared.
The Outcome
More than five years have passed since Wei Junhao's CAR-T infusion. He is alive. He is disease-free. He has no major organ damage.
He does carry some lasting effects from everything his brain endured — partial aphasia, a difficulty with speech, that remains from the trauma of the tumor, the treatment, and the crisis that followed. This is not a small thing, and his family does not minimize it.
But he is here. A young man who had a mutation that made his cancer untreatable by any standard measure, who had a mass the size of a fist pressing against his brain, who was told in every clinical sense that his case was beyond what medicine could do — is alive, more than five years later, without evidence of disease.
His case was selected for inclusion in a landmark Chinese academic publication — a compilation of cellular therapy cases from nearly twenty leading institutions — not because it was easy, but because it revealed something important about what this treatment can do when pushed into territory that protocols have not yet mapped.
Cost Comparison (2026)
CAR-T therapy in China costs roughly $100,000–$150,000 in total, compared with $500,000–$700,000 in the United States — about 70–85% less, using NMPA-approved products at leading hospitals.
🇺🇸 United States | 🇨🇳 China | |
Total cost of care | $500,000 – $700,000 | $100,000 – $150,000 |
Typical / median | ~$608,100 | ≈70–85% lower |
What's included | Drug, hospitalization, CRS/ICANS management, supportive care, follow-up | Drug, hospital stay, cell manufacturing, monitoring, follow-up |
Drug price alone | $373,000 – $475,000 (before hospital costs) | Bundled into total |
Approved products | 6 (FDA) | 7 (NMPA) |
Manufacturing time | 3–5 weeks | 24 hrs – 2 weeks at leading centers |
Time on-site | Local | ~6–10 weeks (incl. monitoring) |
Indicative ranges based on 2025–2026 published data and ChinaCureLInk case coordination. Final quotes depend on diagnosis, product, hospital, and length of stay. Not medical or financial advice.
Considering CAR-T Therapy in China?
Dual-target CAR-T therapy may be an option for selected patients with relapsed or refractory Burkitt lymphoma who have exhausted conventional treatments. Eligibility depends on factors such as disease status, previous therapies, and overall health.
→ Read Full Guide: Is My Child Eligible for CAR-T Therapy?
Learn the key eligibility criteria, required tests, and how to determine if pediatric CAR-T is the right option.
→ Read Full Guide: Relapsed Refractory Leukemia CAR-T Therapy in China – Complete Overview
Learn about leukemia-specific CAR-T protocols and survival outcome data.
What Patients Say About ChinaCureLink & Medebound HEALTH
ChinaCureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot
Medebound HEALTH's online testimonials. Learn More
Conclusion
Burkitt lymphoma remains one of the fastest-growing hematologic malignancies, and outcomes become especially poor after relapse involving the central nervous system.
This case demonstrates how compassionate-use CD19/CD20 dual-target CAR-T therapy enabled long-term disease control in an 18-year-old patient with TP53-mutated, chemotherapy-resistant Burkitt lymphoma after all conventional treatment options had failed.
Although additional clinical studies are required, this case provides encouraging evidence supporting further investigation of dual-target CAR-T therapy for patients with highly aggressive and treatment-resistant Burkitt lymphoma.
→ Read Full Guide: CAR-T Treatment in China – A 2026 Guide for International Patients
Learn about eligibility, treatment options, costs, top hospitals, and what international patients can expect throughout the CAR-T journey.
Frequently Asked Questions
Why do some international patients choose CAR-T therapy in China?
China has become one of the world's leading countries in CAR-T cell therapy research and clinical application. Many hospitals offer access to both commercially approved CAR-T products and innovative dual-target or next-generation CAR-T therapies through clinical studies or compassionate-use programs. Some international patients also choose China because of shorter waiting times and the availability of experienced multidisciplinary teams treating complex blood cancers.
Can international patients receive CAR-T therapy in China?
Yes. Many specialized cancer centers in China accept international patients for CAR-T evaluation and treatment. Before treatment begins, patients typically undergo a comprehensive medical review to determine whether they are suitable candidates based on their diagnosis, previous treatments, overall health, and laboratory findings.
Why was dual-target CAR-T therapy selected in this case?
The patient had relapsed Burkitt lymphoma with a TP53 mutation and central nervous system involvement after failing multiple lines of chemotherapy, radiation therapy, and targeted therapy. Since no standard treatment options remained, the medical team recommended compassionate-use CD19/CD20 dual-target CAR-T therapy to improve the chances of controlling the disease while reducing the risk of antigen escape.
Can CAR-T therapy be used for lymphoma involving the brain or central nervous system?
Although treating central nervous system (CNS) lymphoma remains challenging, growing clinical experience suggests that carefully selected patients may benefit from CAR-T therapy. Because neurological complications can occur, treatment should be performed in experienced centers capable of providing intensive monitoring and supportive care.
What types of lymphoma may be treated with CAR-T therapy in China?
Depending on the hospital and available treatment programs, CAR-T therapy may be considered for several relapsed or refractory B-cell malignancies, including:
Diffuse large B-cell lymphoma (DLBCL)
Burkitt lymphoma
Primary mediastinal B-cell lymphoma
Mantle cell lymphoma
Follicular lymphoma
B-cell acute lymphoblastic leukemia (B-ALL)
Eligibility depends on the patient's individual medical condition and physician evaluation.
How long does CAR-T treatment in China usually take?
For international patients, the complete treatment process generally takes 4 to 8 weeks, although timelines vary depending on the treatment protocol. This typically includes:
Initial consultation and eligibility assessment
Leukapheresis (T-cell collection)
CAR-T cell manufacturing
Lymphodepleting chemotherapy
CAR-T cell infusion
Hospital monitoring and recovery
Patients are usually advised to remain near the treating hospital for several weeks after infusion for close observation.
Is dual-target CAR-T therapy available outside of clinical trials in China?
Availability depends on the specific CAR-T product and hospital. Some dual-target CAR-T therapies may be offered through investigator-initiated studies, compassionate-use programs, or other approved treatment pathways. Eligibility is determined individually after a specialist evaluation.
References
1. CD19 and CD70 Dual-Target Chimeric Antigen Receptor T-Cell Therapy for Relapsed and Refractory Primary Central Nervous System DLBCL — Frontiers in Oncology (PMC), 2019. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6904344/
2. Autologous Hematopoietic Stem Cell Transplantation Followed by CD19/CD22 Dual-Target CAR-T Therapy for Refractory or Relapsed Burkitt Lymphoma — Blood (ASH), 2025. https://ashpublications.org/blood/article/146/Supplement%201/4152/555208/
3. A Novel Loop-Structured CD19/CD22 Dual-Targeting CAR-T Therapy for Patients with Refractory/Relapsed B-Cell Non-Hodgkin Lymphoma — Blood (ASH), 2025. https://ashpublications.org/blood/article/146/Supplement%201/4152/555208/
4. TP53 Mutations and Chemotherapy Resistance in Burkitt Lymphoma — Experimental Hematology & Oncology (PMC), 2015. https://ehoonline.biomedcentral.com/articles/10.1186/s40164-015-0019-9
5. TP53 DNA Binding Domain Mutational Status and Rituximab-Based Treatment as Prognostic Factors in Pediatric Burkitt Lymphoma — PMC, 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11367192/
6. CAR19/22 T-Cell Cocktail Therapy for Refractory Burkitt Lymphoma with TP53 Mutation and 17p Deletion (case report) — American Journal of Hematology (PMC), 2025. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256272/
7. 2022 Chinese Expert Consensus and Guidelines on Clinical Management of Toxicity in Anti-CD19 CAR-T Therapy — Cancer Biology & Medicine (Springer), 2023. https://www.cancerbiomed.org/content/20/2/129
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top 5 cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team that understands both the medical and cultural needs of Southeast Asian patients.
ChinaCureLink is proudly affiliated with Medebound HEALTH— an international medical concierge company headquartered in New York, specialized in securing premium second opinions from top US hospitals and specialists. With over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized as one of the leading patient access services across North America and the Asia Pacific, Medebound HEALTH brings the same standard of expert care coordination to every patient we serve.
This article is for informational purposes only and does not constitute medical advice. All treatment decisions should be made in consultation with a qualified oncologist who has reviewed your complete medical history and current diagnostic information.
Disclaimer
This case study is intended for educational and informational purposes only. Individual treatment outcomes vary based on many factors, including disease characteristics, overall health, prior therapies, and response to treatment. Participation in clinical trials is subject to strict eligibility criteria determined by qualified physicians.
ChinaCureLink is a medical travel facilitation service and does not provide medical diagnosis, treatment, or clinical recommendations. All medical decisions are made by licensed healthcare professionals.
Comments